Amgen Reports Higher Revenue and Profit Across Both Reported Windows in Interim Filing

Bottom line

Across the three-month and six-month year-to-date windows reported in this filing, AMGEN INC (ticker AMGN, CIK 0000318154) posted top-line growth and stronger bottom-line results on a year-over-year basis, while operating income also moved higher in both reporting periods. The interim unaudited condensed consolidated statements, presented under U.S. GAAP, were furnished on form 10-Q for fiscal period period-ended-2026-06-30 and filed under accession 0000318154-26-000126. The filing covers both the three-month reporting period and the six-month year-to-date period, with the prior-year comparative for each window disclosed alongside the current period.

For the three-month reporting period, revenue from contracts with customers excluding assessed tax was $10,054,000,000 USD, higher than the prior-year comparative of $9,179,000,000 USD for the prior-year quarter. Operating income for the quarter was $3,514,000,000 USD, higher than the prior-year quarter figure of $2,656,000,000 USD. Net income attributable to the parent for the three-month reporting period was $2,375,000,000 USD, higher than the prior-year comparative of $1,432,000,000 USD. Earnings per share on a diluted basis for the quarter were $4.37 per diluted share USD/SHARES, higher than the prior-year quarter figure of $2.65 per diluted share USD/SHARES. Both the current and prior periods reflect a profit on a diluted basis.

For the six-month year-to-date period, revenue from contracts with customers excluding assessed tax was $18,672,000,000 USD, higher than the prior-year six-month figure of $17,328,000,000 USD. Operating income for the six-month window was $6,180,000,000 USD, higher than the prior-year comparative of $3,834,000,000 USD. Net income attributable to the parent for the six-month period was $4,194,000,000 USD, higher than the prior-year six-month figure of $3,162,000,000 USD. Earnings per share on a diluted basis for the six-month period were $7.71 per diluted share USD/SHARES, higher than the prior-year six-month figure of $5.84 per diluted share USD/SHARES. Again, both periods reflect a profit on a diluted basis.

The filing evidence does not attribute this change to any single cause.

The reporting basis is clarified in the basis-of-presentation language, which states that the interim unaudited financial information for the three and six months ended in mid-year has been prepared in accordance with GAAP and includes only normal, recurring adjustments, while interim results are not necessarily indicative of results for the full fiscal year. The filing additionally references the Annual Report on Form referenced for the year ended December and the prior Quarterly Report on Form 10-Q for the quarter ended March for continuity; segment-level detail is addressed in the cited segment information note within Part I.

Additional context for this analysis is available on the Finance Calculators insights hub.

Financial performance

For the three-month reporting period, Amgen reported Revenue from Contract with Customer, Excluding Assessed Tax that was higher than the prior-year comparative, with both periods positive. Operating Income (Loss) for the same quarter was higher than the prior-year quarter, and both periods remained profitable. Net Income (Loss) Attributable to Parent for the quarter was higher than the prior-year quarter, continuing a profit-to-profit pattern. Earnings Per Share, Diluted for the quarter was higher than the prior-year quarter, again with both periods profitable.

For the six-month year-to-date period, Revenue from Contract with Customer, Excluding Assessed Tax was higher than the prior-year comparative, with both periods positive. Operating Income (Loss) for the six-month window was higher than the prior-year comparative, with both periods profitable. Net Income (Loss) Attributable to Parent for the six-month window was higher than the prior-year comparative, maintaining a profit-to-profit transition. Earnings Per Share, Diluted for the six-month window was higher than the prior-year comparative, with both periods profitable. The filing evidence does not attribute this change to any single cause.

The interim results are not necessarily indicative of full-year results, and the condensed consolidated statements should be read alongside the prior Annual Report on Form referenced in the basis-of-presentation note. Certain prior-period amounts have been reclassified to conform with the current presentation. Amgen operates as a single operating and reportable segment, human therapeutics, with the Chief Executive Officer identified as the chief operating decision maker reviewing consolidated net income to allocate resources.

Regarding pending accounting changes, a recent FASB update on expense disaggregation has been issued; Amgen is currently evaluating the impact of adopting this standard on its consolidated financial statements and related disclosures, with the standard effective for annual and interim periods beginning after the cited future year-end. The filing evidence does not attribute this change to any single cause.

For the year-to-date window, other segment items primarily consisted of impairment charges on intangible assets (referenced in the goodwill and other intangible assets note) and fair value adjustments on equity securities (referenced in the investments note). For the quarter, other segment items primarily consisted of fair value adjustments on equity securities (referenced in the investments note). In the prior-year comparative periods, other segment items primarily consisted of fair value adjustments on equity securities and litigation expenses and settlements.

The filing evidence contains no forward-looking guidance commentary from management regarding expected future revenue, operating income, net income, or earnings-per-share levels; the filing provides reported results and accounting context only. The filing evidence contains no peer or industry comparison. The filing evidence also does not include any specific commentary from analysts on these interim results. Management's own narrative focuses on the basis of presentation, the single-segment structure, the CODM's use of consolidated net income for resource allocation, the pending expense-disaggregation standard, and the nature of other segment items in each reporting window.

Readers evaluating the year-to-date versus quarter profile should note that the six-month window captures both the impairment-related other segment items and the equity-securities fair-value adjustments, while the standalone quarter captures only the latter, which is consistent with the comparative baselines presented above but does not, on its own, explain the direction of the changes shown. The filing evidence does not attribute this change to any single cause.

Operating drivers and segments

- Amgen operates as a single reportable segment — human therapeutics — so the consolidated income statement is the only segment view available; no separate product, geography or therapeutic-area margins are disclosed in this filing. - Within that one segment, the measure reviewed by the CODM is segment net income on a consolidated basis, and the measure of segment assets is total assets, also on a consolidated basis. - Segment net income for the three-month reporting period was higher than the prior-year three-month period (authorized direction: increase; transition profit to profit). - Segment net income for the six-month year-to-date period was higher than the prior-year six-month period (authorized direction: increase; transition profit to profit). - Revenue from contract with customer for the three-month reporting period was higher than the prior-year three-month period (authorized direction: increase). - Revenue from contract with customer for the six-month year-to-date period was higher than the prior-year six-month period (authorized direction: increase). - Operating income for the three-month reporting period was higher than the prior-year three-month period (authorized direction: increase; transition profit to profit). - Operating income for the six-month year-to-date period was higher than the prior-year six-month period (authorized direction: increase; transition profit to profit). - For the six-month year-to-date period, other segment items touched segment net income through (i) intangible-asset impairment charges (per the cited note on goodwill and other intangible assets) and (ii) fair-value adjustments on equity securities (per the cited note on investments), so part of the segment profitability picture is shaped by those non-operating or non-cash items rather than core product economics alone. - For the three-month reporting period, other segment items consisted primarily of fair-value adjustments on equity securities, with litigation expenses and settlements also called out as a component; the filing does not size these items in dollar terms.

- Management frames the business as one operating and one reportable segment — human therapeutics — covering discovery, development, manufacturing and delivery of innovative medicines, with consolidated review by the CODM. - Management does not, in the cited narrative, attribute the year-over-year improvement in revenue, operating income or segment net income to any single product, pricing action, geographic mix or cost lever; the filing simply presents the higher comparative numbers without a written driver story. - Management flags that other segment items — fair-value movements on equity securities and, for the year-to-date period, intangible-asset impairments — are treated outside the core operating picture and are disclosed separately, signalling management's own segmentation of what is and is not core to the human-therapeutics result. - Management also notes that the July MFN Letter and the Inflation Reduction Act of the cited year are part of the regulatory environment, but the filing text provided does not quantify their effect on revenue, operating income or segment net income for either the quarter or the half-year window. - Net Cash Provided by Operating Activities was higher than the prior-year six-month comparative (authorized direction: increase), while Payments to Acquire Property, Plant, and Equipment were higher than the prior-year six-month comparative (authorized direction: increase) and Payments of Ordinary Dividends, Common Stock were higher than the prior-year six-month comparative (authorized direction: increase) — capital return and capital spending both stepped up alongside the operating improvement. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

Cash flow and capital

AMGEN INC (CIK 0000318154, ticker AMGN) filed its period-ended-2026-06-30 report on 10-Q under accession 0000318154-26-000126. Cash flow reporting in the cited evidence is restricted to the six-month year-to-date window, so the analysis below covers the year-to-date cash flow statement alongside the balance sheet snapshot at the balance sheet date of June 30, 2026.

Reported facts (as recorded on the statement of cash flows for the six months ended the six months ended June 30, 2026): - Operating activities: $6,191,000,000 (prior year: $3,671,000,000). - Investing activities: -$1,285,000,000 (prior year: -$836,000,000). - Financing activities: -$46,000,000 (prior year: -$6,780,000,000).

Management explanations drawn from the cited evidence: - The CODM manages the company as a single human therapeutics segment on a consolidated basis, using net income to allocate resources across functions, therapeutic areas, regions and R&D programs, and references net cash used in investing activities together with the disclosure in the cited note on Investments as the lens through which capital expenditures are evaluated. - Other segment items affecting net income included fair value adjustments on equity securities in both the three- and six-month windows, and impairment charges on intangible assets in the six-month window, each tied to specific notes in the cited evidence. - The cited evidence also explains that the effective tax rate rose year over year in both windows, citing earnings mix (including lower amortization from acquisition-related assets) and, for the six-month period, a swing from prior-period net unrealized gains to current-period net unrealized losses on equity investments, though these are tax-line drivers rather than cash flow drivers.

Analyst inference (only what the cited evidence supports): - The operating cash flow line moved in the authorized direction of increase year over year on a positive base, while the investing line moved in the authorized direction of decrease year over year on a negative base, and the financing line moved in the authorized direction of increase year over year on a negative base. The financing move means the cash outflow became smaller rather than that financing turned inflow-positive. - Capital expenditures, captured in $1,225,000,000 (prior year: $780,000,000), sit inside the investing line and are authorized to have increased year over year on a positive base, indicating that the investing deterioration did not stem from a pullback in property, plant and equipment spending. - Ordinary common stock dividends, $2,720,000,000 (prior year: $2,559,000,000), are authorized to have increased year over year on a positive base, consistent with a rising dividend payout profile within financing outflows.

Counter-evidence and reconciliation flags: - The cited evidence discloses that the company and its subsidiaries are now subject to a minimum tax rate on adjusted financial statement income following the global minimum tax enactments noted; this is a tax-rate observation, not a cash flow driver in the catalog. - The cash flow statement and the balance sheet below do not tie out in the cited excerpt, so any inferred "free cash flow" cannot be reconstructed from the catalog without borrowing a digit. - The cited evidence also flags IRS RARs and U.S. Tax Court proceedings relating to profit allocation between U.S. and Puerto Rico entities, which is a contingent exposure rather than a settled cash outflow.

Balance sheet posture at the balance sheet date of June 30, 2026: - Cash and cash equivalents: $13,989,000,000. - Long-term debt, excluding current maturities: $51,859,000,000. - Accounts payable, current: $2,865,000,000. - These three lines are presented without inter-line ratios because the cited evidence provides no computed leverage, coverage or liquidity ratios and the rules prohibit any computation on my part.

Unknowns / not stated in the cited evidence: - Stock repurchase activity and treasury share movement are not present in the catalog for this section. - The split between the two components of net cash used in investing activities (capital expenditures versus other investing outflows, such as acquisitions or marketable securities activity) is not separately broken out in the cited evidence beyond the capex figure, so the residual investing outflow is not analyzable here. - No cash and debt figures are given for the prior balance sheet date, so the period-over-period change in liquidity and leverage is not derivable from the cited evidence. - Peer benchmarking is not provided in the cited evidence; The filing evidence contains no peer or industry comparison..

Causality discipline: - For the year-over-year changes in operating, investing, financing, capex and dividends, no cause is authorized. The filing evidence does not attribute this change to any single cause. - For the cash balance, long-term debt and accounts payable movements between reporting dates, no cause is authorized. The filing evidence does not attribute this change to any single cause.

Peer and historical context

- Amgen's reported revenue moved higher year over year in both the three-month reporting window and the six-month year-to-date window, continuing the top-line trajectory observed across the prior comparative period. - Net income attributable to the parent followed the same direction, rising in both the quarter and the half-year on a year-over-year basis, with both periods remaining in profit relative to their prior-year counterparts. - Operating income traced a comparable path, increasing in the quarter and the half-year when set against the prior-year comparative periods, and staying in profit territory on both sides of the comparison.

- Operating cash flow for the half-year also expanded relative to the prior-year comparative, reinforcing the income-statement improvements with a stronger cash-generation signal. - The direction of change is uniform across revenue, operating income, net income, and operating cash flow, which points to a broadly consistent year-over-year improvement rather than a single-line distortion. - The effective tax rate commentary in the filing attributes the rate increase partly to a change in earnings mix, including lower amortization expense from acquisition-related assets, and partly to net unrealized investment losses versus prior-year gains — context the income statement alone does not surface.

- For peer benchmarking against other large biopharmaceutical issuers, the section relies solely on the company-reported figures in this interim filing, since no third-party peer dataset is contained in the filing evidence. - Reported facts in this section are limited to the income-statement and cash-flow lines above; balance-sheet, share-count, and segment-level figures are not part of this comparison. - No cause-and-effect language is offered for the year-over-year movement; the filing narrative does not isolate a single driver for the directional shift in revenue, operating income, or net income.

- Where peer or industry context would normally be discussed, the comparison here is strictly historical against the prior-year periods filed by the same registrant.

Scenario analysis

- In the base case, AMGEN INC continues to deliver a higher revenue line and a higher bottom line in both reporting windows, on the back of the year-to-date and three-month growth shown in the filing. Revenue from Contract with Customer, Excluding Assessed Tax rose for the six months ended June 30, 2026 versus the six months ended June 30, 2025 (see $18,672,000,000 and $17,328,000,000), and it also rose for the three months ended June 30, 2026 versus the three months ended June 30, 2025 (see $10,054,000,000 and $9,179,000,000).

Net Income (Loss) Attributable to Parent likewise increased across both windows, with the year-to-date figure at $4,194,000,000 against the prior year-to-date $3,162,000,000, and the three-month figure at $2,375,000,000 against the prior-year quarter $1,432,000,000. The base path assumes this trajectory persists, with the authorized profit-to-profit transition holding in both windows; The filing evidence does not attribute this change to any single cause.. - The upside case layers two constructive assumptions on top of the base.

First, the momentum visible in $18,672,000,000 versus $17,328,000,000 and in $10,054,000,000 versus $9,179,000,000 extends through the balance of the fiscal year, lifting the full-year top line above the run-rate implied by the half-year total. Second, the operating leverage implied by the year-to-date and three-month profit comparisons ($4,194,000,000 against $3,162,000,000, and $2,375,000,000 against $1,432,000,000) carries forward, so margin expansion continues at a pace consistent with the authorized profit-to-profit transitions reported for both Net Income (Loss) Attributable to Parent and Operating Income (Loss).

The base evidence does not authorize any cause-and-effect attribution, so the upside remains a directionally favorable continuation rather than a sourced driver story; The filing evidence does not attribute this change to any single cause.. - The downside case anchors on the tax-side disclosures in the source narrative. The Company and its subsidiaries are now subject to a higher minimum tax rate on adjusted financial statement income under the newly enacted scope of the agreement referenced in the filing, with most provisions effective as of the start of the next calendar year.

On top of that, the IRS-related matters described — including the Tax Court proceedings on the Notices for the cited years, the reissued NOPA for the later years, and the open audit for the subsequent years — are explicitly flagged as having the potential to require payments substantially greater than the accrued amounts, with the possibility of a material adverse impact on the condensed consolidated financial statements. Should any of these matters resolve unfavorably, the higher revenue baseline established by $18,672,000,000 and $10,054,000,000 and the higher profit baseline established by $4,194,000,000 and $2,375,000,000 could compress, interrupting the authorized profit-to-profit transition in Operating Income (Loss) and Net Income (Loss) Attributable to Parent; The filing evidence does not attribute this change to any single cause..

- Cross-cutting note for all three scenarios: the filing does not disclose segment-level economics or peer benchmarks for any of the figures above, so the scenarios rest entirely on the consolidated trajectory and the cited tax narrative; The filing evidence contains no peer or industry comparison. and The filing evidence does not disclose segment-level detail for this dimension.. See the operating-segment discussion in the cited note for the only segment framing the evidence supports.

Readers building their own base, upside, or downside ranges should weigh the tax exposures flagged above against the top-line and bottom-line momentum captured in the half-year and three-month comparisons summarized here; this is informational framing rather than advice, and no price target or transaction recommendation is offered.

Risks and what to watch

S. tax position. S.

S. territory of Puerto Rico, plus an active IRS examination that reissued a draft notice of proposed adjustment in substantially the same form. Management states the proposed adjustments, if sustained in full, could have a material impact on the financial statements, and warns that the ultimate outcome may produce payments substantially greater than amounts accrued, with final resolution not likely within the next several months.

The cited note in Note 13 is the standing reference for these income-tax matters. - A second tax-related risk is balance-sheet uncertainty. Management discloses that gross unrecognized tax benefits increased during both the three- and six-month periods reported in 10-Q period-ended-2026-06-30 as a result of current-year tax positions, raising the magnitude of the contingent obligation if any portion is later disallowed.

Catalysts to watch on this front are any change in the methodology used by the audit team, any shift from the audit team toward positions previously argued by the IRS elsewhere, and the timetable for the pending Tax Court oral argument and post-trial briefing pipeline described in the narrative. - Counter-evidence to a deteriorating picture is built into the authorized comparisons on the top and bottom lines. Revenue from Contract with Customer, Excluding Assessed Tax is shown higher year over year in both the three months ended June 30, 2026 versus the three months ended June 30, 2025 and the six months ended June 30, 2026 versus the six months ended June 30, 2025, and Net Income (Loss) Attributable to Parent is also higher in both windows on a year-over-year basis, with the transition remaining in profit territory across the quarter and the year-to-date.

That profile is the principal factual offset against the tax overhang. - Unknowns explicitly left unresolved by the filing evidence include the dollar amount of any potential settlement, the timing of final Tax Court resolution, the probability management assigns to a particular outcome, and the segment-level distribution of revenue across the reported periods. The filing provides no peer or industry comparison and does not disclose segment-level detail for the reported dimensions.

- Counter-evidence also lives in segment-reporting ambiguity. The cited segment note (Note 2) sets the basis of presentation for interim results but does not, in the quoted evidence, break out revenue or operating performance by reportable segment in a way this section can use. - Additional referenced risk areas appear elsewhere in the filing but are not detailed in the quoted evidence, including goodwill and intangible asset considerations (Note 8), equity method investments (Note 6), market risk disclosures (Item 3), controls and procedures (Item 4), and the legal proceedings and risk-factor sections (Item 1 and Item 1A).

Those sections are flagged so a reader can monitor them next period rather than treating them as confirmed risk drivers for the current filing. - Management explanation of the tax contingency is that the company disagrees with the IRS methodology, believes the positions are without merit, and considers the existing accrual appropriate based on past experience, interpretations of tax law, and judgments about potential tax-authority actions. The company also notes it has informed the audit team of perceived inconsistencies relative to positions taken by the IRS elsewhere, which the company reads as more favorable to Amgen than the prior audit-team stance.

- Analyst inference from the authorized comparisons is limited to qualitative direction. Revenue and net income are both higher year over year in the quarter and the year-to-date. The filing evidence does not attribute this change to any single cause.

- Peer-context note: The filing evidence contains no peer or industry comparison. - Segment-detail note: The filing evidence does not disclose segment-level detail for this dimension. - Metrics to watch next period are the reported revenue total for the next quarter and year-to-date versus the prior-year comparatives, the corresponding net income line, the gross unrecognized-tax-benefits balance and any further movement in the Puerto Rico allocation matter, and any procedural developments in the Tax Court case and the open IRS examination.

Readers interested in the broader finance context for these filings can explore the Finance Calculators insights hub.